[HTML][HTML] iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders
H Okano, S Morimoto - Cell Stem Cell, 2022 - cell.com
It has been 15 years since the birth of human induced pluripotent stem cell (iPSC)
technology in 2007, and the scope of its application has been expanding. In addition to the …
technology in 2007, and the scope of its application has been expanding. In addition to the …
iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders
H Okano, S Morimoto - Cell stem cell, 2022 - pubmed.ncbi.nlm.nih.gov
It has been 15 years since the birth of human induced pluripotent stem cell (iPSC)
technology in 2007, and the scope of its application has been expanding. In addition to the …
technology in 2007, and the scope of its application has been expanding. In addition to the …
iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders
H Okano, S Morimoto - Cell stem cell, 2022 - keio.elsevierpure.com
抄録 It has been 15 years since the birth of human induced pluripotent stem cell (iPSC)
technology in 2007, and the scope of its application has been expanding. In addition to the …
technology in 2007, and the scope of its application has been expanding. In addition to the …
[HTML][HTML] iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders
H Okano, S Morimoto - Cell Stem Cell, 2022 - Elsevier
It has been 15 years since the birth of human induced pluripotent stem cell (iPSC)
technology in 2007, and the scope of its application has been expanding. In addition to the …
technology in 2007, and the scope of its application has been expanding. In addition to the …
[HTML][HTML] iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders
H Okano, S Morimoto - Cell Stem Cell, 2022 - cell.com
It has been 15 years since the birth of human induced pluripotent stem cell (iPSC)
technology in 2007, and the scope of its application has been expanding. In addition to the …
technology in 2007, and the scope of its application has been expanding. In addition to the …
[引用][C] iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders
H Okano, S Morimoto - Cell Stem Cell, 2022 - cir.nii.ac.jp
iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders |
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders.
H Okano, S Morimoto - Cell Stem Cell, 2022 - europepmc.org
It has been 15 years since the birth of human induced pluripotent stem cell (iPSC)
technology in 2007, and the scope of its application has been expanding. In addition to the …
technology in 2007, and the scope of its application has been expanding. In addition to the …
iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders
H Okano, S Morimoto - Cell stem cell, 2022 - keio.elsevierpure.com
It has been 15 years since the birth of human induced pluripotent stem cell (iPSC)
technology in 2007, and the scope of its application has been expanding. In addition to the …
technology in 2007, and the scope of its application has been expanding. In addition to the …